Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate Cancer
a study on Prostate Cancer
Summary
- Eligibility
- for males ages 18 years and up (full criteria)
- Location
- at San Francisco, California
- Dates
- study startedcompletion around
- Principal Investigator
- by Daniel Kwon, MD
Description
Summary
The overall goal of the study is to improve equitable delivery of pre-Tumor genetic testing (TGT) counseling tool for Black or African American men with metastatic prostate cancer and evaluating the tool for implementation.
Official Title
Developing and Testing a Patient-centered Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Metastatic Prostate Cancer
Details
PRIMARY OBJECTIVES:
Stage 1: To evaluate education quality of the intervention in Black or African American men with prostate cancer.
Stage 2: To evaluate feasibility of the TGT intervention among Black or African American men with prostate cancer
SECONDARY OBJECTIVES:
Stage 1:
- To evaluate completeness of the intervention content.
- To identify barriers and facilitators for using the intervention.
Stage 2:
- To evaluate the acceptability of the intervention among Black or African American men with prostate cancer.
- To evaluate change in participant knowledge about tumor genetic testing among Black or African American men with prostate cancer.
- To evaluate change in patient attitudes toward tumor genetic testing among Black or African American men with prostate cancer.
- To evaluate change in participant expectations of tumor genetic testing among Black or African American men with prostate cancer.
- To evaluate patient perspectives on the intervention.
- To evaluate the rate of TGT among Black or African American men with prostate cancer who have received the tumor genetic pre-test counseling tool.
OUTLINE:
This is a two-stage study. In Stage 1, Adult Black or African American men with metastatic prostate cancer who have not made a decision about TGT, or who have decided to undergo TGT, or patients who have decline TGT about tumor genetic testing will participate in development by answering questionnaires and utilizing the pilot application for up to 60 days. The investigators will then refine the tool to be piloted in Stage 2.
Stage 2: A pilot study of participants who are planning to have a discussion about undergoing tumor genetic testing with their oncology provider will be invited to join and utilize the tool, and answer questionnaires about the tool.
Keywords
Prostate Cancer, Prostate Cancer Metastatic, Prostatic Neoplasms
Eligibility
You can join if…
Open to males ages 18 years and up
Stage 1:
- Age 18-years-old or older
- Identifies as Black or African American, by either chart documentation or participant self-report. Mixed-race including Black or African American is included.
- Metastatic prostate cancer, by either chart documentation or participant self-report. Pathology report not needed.
- Able to understand study procedures and to comply with them for the entire length of the study.
- Able to understand a written information sheet and willing to verbally consent.
- Fluent in English (reading, writing, and speaking)
Stage 2:
- Age 18-years-old or older
- Identifies as Black or African-American, by either chart documentation or participant self-report. Mixed-race including Black or African-American is included.
- Metastatic prostate cancer, by either chart documentation or participant self-report. Pathology report not needed.
- Able to understand study procedures and to comply with them for the entire length of the study.
- Fluent in English (reading, writing, and speaking).
- Anticipated discussion of TGT within 0-90 days of enrollment, per treating oncology provider's discretion. TGT involves use of any cancer genetic sequencing (whether standard-of-care or part of a research protocol) via any one of the following:
- Somatic DNA testing of already-collected tissue.
- Somatic DNA testing of tissue to be collected in the future via biopsy, surgery, or other procedure.
- Blood-based DNA testing to evaluate for circulating tumor DNA.
- Able to understand a written informed consent document and willing to sign it.
You CAN'T join if...
Contraindication to any study-related procedure or assessment in either stage.
Location
- University of California
accepting new patients
San Francisco California 94143 United States
Lead Scientist at UCSF
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- University of California, San Francisco
- ID
- NCT06171139
- Study Type
- Interventional
- Participants
- Expecting 80 study participants
- Last Updated
Frequently Asked Questions
Please contact me about this study
We will not share your information with anyone other than the team in charge of this study, which might include an external sponsor. Submitting your contact information does not obligate you to participate in research.
Thank you!
The study team should get back to you in a few business days.
You will also receive an email with next steps. Check your junk/spam folder if needed.
If you do not hear from the study team, please call 888-689-8273 and tell them you’re interested in study number NCT06171139.